A. Vocat

Type de document

Articles (5)

Co-auteur

Date

Source

Mot-clé

Treatment (4) Tuberculosis (4) Mycobacterium tuberculosis (4) Tuberculosis (4) thérapie (3) antibiotique (3) méthode (3) Methods (3) Therapeutics (3) Human beings (3) Methods (3) technologie (2) norme (2) protocole (2) métabolite (2) mesure (méthode analytique) (2) hôpital (2) exposition (2) chromatographie (2) Identification (2) Metabolites (2) World health (2) Technology (2) Stability (2) Mice (2) Measurement (2) Identification (2) Drugs (2) Chromatographic analysis (2) Multidrug-resistant tuberculosis (2)

Documents écrit par A. Vocat (5) | parle de A. Vocat (0)

Nanomotion technology in combination with machine learning: a new approach for a rapid antibiotic susceptibility test for Mycobacterium tuberculosis.
A. Vocat et al.
Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine.
V. Desfontaine et al. (15 janv. 2023)
Investigating nanomotion-based technology (Resistell AST) for rapid antibiotic susceptibility testing among adult patients admitted to a tertiary-care hospital with Gram-negative bacteraemia: protocol for a prospective, observational, cross-sectional, single-arm study.
G. Caruana et al. (21 nov. 2022)
Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma.
D. Spaggiari et al. (2019)
Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
V. Makarov et al. (2014)